Because standard-of-care medications such as statins may be less effective in preventing stroke in patients with advanced CKD [43], the benefits of SGLT2 inhibitors, despite the short period of follow-up in these CVOTs, stood out most prominently. This evidence concerns the gene SLC5A2 and chronic kidney disease.